TP53 Mutations in Myelodysplastic Syndrome

References

• Zambetti G. P., Levine A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993; 7: 855–865
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• De Fromentel C. C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromo & Cancer 1992; 4: 1–15
   PubMed Web of Science ®Google Scholar
• Greenblall M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855–4878
   PubMed Web of Science ®Google Scholar
• Fenaux P., D'Hooghe M. C., Jonveaux P., Lai J. L., Bauters F., Loucheux M. H., Kerckaert J. P. Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia. Nouv. Rev. Fr. Hematol. 1990; 32: 341–344
   PubMedGoogle Scholar
• Ahuja H., Bar-Eli M., Advani S. H., Benchimol S., Cline M. J. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. USA 1989; 86: 6783–6787
   PubMed Web of Science ®Google Scholar
• Kelman Z., Prokocimer M., Peller S., Kahn Y., Rechavi G., Manor Y., Cohen A., Rotter V. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1989; 74: 2318–2324
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Arlin Z., Advani S., Allen S. L., Goldman J., Snyder D., Foti A., Cline M. J. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest. 1991; 87: 2042–2047
   PubMed Web of Science ®Google Scholar
• Jonveaux P., Fenaux P., Quiquandon I., Pignon J. M., Lai J. L., Loucheux-Lefebvre M. H., Goossens M., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991; 6: 2243–2247
   PubMed Web of Science ®Google Scholar
• Ludwig L., Schulz A. S., Janssen W. G., Gruenewald K., Bartram C. R. P53 mutations in myelodysplastic syndromes. Leukemia 1992; 6: 1302–1304
   PubMed Web of Science ®Google Scholar
• Mori N., Wada M., Yokota J., Terada M., Okada M., Teramura M., Masuda M., Hoshino S., Motoji T., Oshimi K., Mizoguchi H. Mutations of the p53 tumor suppressor gene in hematologic neoplasms. Brit. J. Haematol. 1992; 81: 235–240
   PubMed Web of Science ®Google Scholar
• Tsushita K., Hotta T., Ichikawa A., Saito H. Mutation of p53 gene does not play a critical role in myelodysplastic syndrome and its transformation to acute leukemia. Br. J. Haematol. 1992; 82: 456–457
   Web of Science ®Google Scholar
• Sugimoto K., Hirano N., Toyoshima H., Chiba S., Mano H., Takaku F., Yazaki Y., Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022–3026
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Kaneko H., Misawa S., Horiike S., Nakai H., Kashima K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995; 85: 2189–2193
   PubMed Web of Science ®Google Scholar
• Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkit lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jonveaux P., Quiquandon I., Preudhomme C., Lai J. L., Vanrumbeke M., Loucheux-Lefebvre M. H., Bauters F., Berger R., Kerckaert J. P. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 1992; 6: 42–46
   PubMed Web of Science ®Google Scholar
• Ichikawa A., Hotta T., Takagi N., Tsushita K., Kinoshita T., Nagai H., Murakami Y., Hayashi K., Saito H. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992; 79: 2701–2707
   PubMed Web of Science ®Google Scholar
• Sander C. A., Yano T., Clark H. M., Harris C., Longo D. L., Jaffe E. S., Raffeld M. P53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994–2004
   PubMed Web of Science ®Google Scholar
• Wada M., Bartram C. R., Nakamura H., Hachiya M., Chen D., Borenslein J., Miller C. W., Ludwig L., Hansen-Hagge T. E., Ludwig W. D., Reiter A., Mizoguchi H., Koeffler H. P. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163–3169
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Toguchida J., Yandell D. W., Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res. 1992; 52: 6588–6593
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S. Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. Leukemia and Lymphoma 1995; 19: 213–221
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jonveaux P., Quiquandon I., Lai J. L., Pignon J. M., Loucheux-Lefebvre M. H., Bauters F., Berger R., Kerckaert J. P. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78: 1652–1657
   PubMed Web of Science ®Google Scholar
• Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A. T. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128–135
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K., Hirai H., Ishikawa F., Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–1156
   PubMed Web of Science ®Google Scholar
• Horiike S., Taniwaki M., Misawa S., Abe T. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 1988; 62: 1129–1138
   PubMed Web of Science ®Google Scholar
• Lai J. L., Preudhomme C., Zandecki M., Flactif M., Vanrumbeke M., Lepelley P., Wattel E., Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. an entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995; 9: 370–381
   PubMed Web of Science ®Google Scholar
• Nakai H., Kaneko H., Nakao M., Horiike S., Misawa S. Is inactivation of the p53 gene a common event in leukemias and myelodysplastic syndrome with monosomy 17p?. Leukemia 1994; 8: 1247–1248
   PubMed Web of Science ®Google Scholar
• Lane D. P. p53, guardian of the genome. Nature 1992; 358: 15–16
   PubMed Web of Science ®Google Scholar
• Horiike S., Misawa S., Nakai H., Kaneko H., Yokota S., Taniwaki M., Yamane Y., Inazawa J., Abe T., Kashima K. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994; 8: 1331–1336
   PubMed Web of Science ®Google Scholar
• Parada L. F., Land H., Weinberg R. A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature 1984; 312: 649–651
   PubMed Web of Science ®Google Scholar
• Pallegata N. S., Sessa F., Renaut B., Bonato M., Leone B. E., Salcia E., Ranzani G. N. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994; 54: 1556–1560
   PubMed Web of Science ®Google Scholar
• Sessa F., Pellegata N. S., Bonato M., Capella C., Solcia E., Kloppel G., Ranzani G. N. Mutation of p53 and K-ras in intraductal papillary tumor are related to grade of epithelial dysplasia. Digestion 1993; 54: 308–309
   Google Scholar
• Lehman T. A., Bennett W. P., Metcalf R. A., Welsh J. A., Eckeer J., Modali R. V., Ullrich S., Romano J. W., Appella E., Testa J. R., Gerwin B. I., Harris C. C. p53 mutations. ras mutations and p53-heat-shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991; 51: 4090–4096
   PubMed Web of Science ®Google Scholar
• Mitsudomi T., Steinberg S. M., Nau M. M., Carbone D., D'Amico D., Bodner S., Oie H. K., Linnoila R. I., Mullshine J. L., Minna J. D., Gazdar A. F. P53 mutations in non-small-cell-lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171–180
   PubMed Web of Science ®Google Scholar
• Wolf D., Rotter V. Major deletions in the gene coding the p53 tumor antigen cause lack of p53 expression in HL60 cells. Pre. Natl. Acad. Sci. USA 1985; 82: 790–794
   PubMed Web of Science ®Google Scholar
• Bos J., Verlaan-De Vries M., Jansen A., Veeneman G., Van Boon J., Vander Eb A. Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res. 1984; 12: 9155–9162
   PubMed Web of Science ®Google Scholar
• Gaidano G., Guerrasio A., Serra A., Carozzi F., Cambrin G. R., Petroni D., Saglio G. Mutations in the p53 and ras family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia 1993; 7: 946–953
   PubMed Web of Science ®Google Scholar
• Buhler-Leclerc M., Gratwohl A., Senn H. P. Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukaemia carring an activating N-ras mutation. Brit. J. Haematol. 1993; 84: 443–450
   PubMed Web of Science ®Google Scholar
• Hollstein M. C., Peri L., Mandard A. M., Welsh J. A., Montesano R., Metcalf R. A., Bak M., Harris C. C. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res. 1991; 51: 4102–4103
   PubMed Web of Science ®Google Scholar
• Bashey A., Gill R., Levi S., Farr C. J., Clutterbuck R., Miller J. L., Pragnell I. B., Marshall C. J. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML) implications for the role of N-ras mutation in AML pathogenesis. Blood 1992; 79: 981–989
   PubMed Web of Science ®Google Scholar
• Van Kamp H., De Pijper C., De Vries M. V., Bos J. L., Leeksma C. H. W., Krekhofs H., Willemze R., Fibbe W. E., Landegent J. E. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992; 79: 1266–1270
   PubMed Web of Science ®Google Scholar
• Hsu I. C., Metcalf R. A., Sun T., Welsh J., Wan N. J., Harris C. C. p53 gene mutational hotspot in human hepatocellular carcinomas from Qidong, China. Nature 1991; 350: 427–428
   PubMed Web of Science ®Google Scholar
• Slingerland J. M., Minden M. D., Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood 1991; 77: 1500–1507
   PubMed Web of Science ®Google Scholar
• Cesarman E., Chadburn A., Inghirami G., Gaidano G., Knowles D. M. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992; 80: 3205–3216
   PubMed Web of Science ®Google Scholar
• Sakashita A., Hattori T., Miller C. W., Suzushima H., Asou N., Takatsuki K., Koeffler H. P. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79: 477–480
   PubMed Web of Science ®Google Scholar
• Bhatia K. G., Gutierrez M. I., Huppi K., Siwarski D., Magrath I. T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 1992; 52: 4273–4276
   PubMed Web of Science ®Google Scholar
• Neubauer A., He M., Schmidt C. A., Huhn D., Liu E. T. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 1993; 7: 593–600
   PubMed Web of Science ®Google Scholar
• Gaidano G., Serra A., Guerrasio A., Rege-Cambrin G., Mazza U, Saglio G. Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. Ann. Hematol. 1994; 68: 3–7
   PubMed Web of Science ®Google Scholar
• Le Beau M. M., Albain K. S., Larson R. A., Vardiman J. W., Davis E. M., Blough R. B., Golomb H. M., Rowley J. D. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlympho-cytic leukemia: further evidence for characteristic abnormalities of chromosomes No. 5 and 7. J. Clin. Oncol. 1986; 4: 325–345
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P., Larsen S. O., Andersson M., Daugaard G., Ersboell J., Hansen S. W., Hou-Jensen K., Nielsen D., Sigsgaard T. C., Specht L., Oesterlind K. Therapyrelated myelodysplasia and acute myeloid leukemia, cytogenetic characteristics of 115 concecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen Series. Leukemia 1993; 7: 1975–1986
   PubMed Web of Science ®Google Scholar